Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from ALX Oncology Holdings ( (ALXO) ).
On September 11, 2025, ALX Oncology Holdings announced significant management changes, including the resignation of Dr. Alan Sandler as Chief Medical Officer, effective September 26, 2025, to pursue other opportunities. Dr. Barbara Klencke, a board member with extensive experience in oncology drug development, will assume the role of interim Chief Medical Officer on September 17, 2025, to ensure a smooth transition. The company also regained compliance with Nasdaq’s minimum bid price requirement on September 4, 2025, which stabilizes its market position. These changes are part of ALX Oncology’s strategy to advance its clinical programs, particularly the development of evorpacept and ALX2004, under the leadership of Dr. Klencke.
The most recent analyst rating on (ALXO) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on ALX Oncology Holdings stock, see the ALXO Stock Forecast page.
Spark’s Take on ALXO Stock
According to Spark, TipRanks’ AI Analyst, ALXO is a Underperform.
ALX Oncology Holdings faces significant financial hurdles due to ongoing losses and negative cash flow, reflected in its low financial performance score. The technical analysis indicates a bearish trend with the stock trading below major moving averages. The valuation is challenging due to a negative P/E ratio and lack of dividends. Recent corporate events offer some hope with new leadership appointments, though offset by workforce reductions. Overall, the challenges outweigh the positive aspects, resulting in a low overall stock score.
To see Spark’s full report on ALXO stock, click here.
More about ALX Oncology Holdings
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel therapies to treat cancer and extend patients’ lives. The company’s lead therapeutic candidate, evorpacept, is being evaluated in multiple clinical trials for various cancer indications. ALX Oncology is also advancing ALX2004, a novel EGFR-targeted antibody-drug conjugate, which entered Phase 1 trials in August 2025.
Average Trading Volume: 927,100
Technical Sentiment Signal: Sell
Current Market Cap: $63.19M
For detailed information about ALXO stock, go to TipRanks’ Stock Analysis page.